Anthony Ngo, PharmD, CentraCare-St. Cloud
On March 19, 2026, the U.S. Food and Drug Administration (FDA) approved a higher dose formulation of Wegovy® Injection (7.2 mg), called Wegovy® HD, for weight loss and long-term maintenance for adults with obesity or overweight with at least 1 one-weight related condition (e.g. untreated dyslipidemia or hypertension). Wegovy® HD became the first glucagon-like peptide-1 (GLP-1) receptor agonist approved through the FDA Commissioner’s National Priority Voucher Pilot Program, which accelerates review timelines for therapies aligned with national health priorities. Approval occurred within 54 days, compared with the standard FDA review timeline of approximately 10 months or 6 months under priority review pathways used for previously approved GLP-1 receptor agonists.
Approval was based on results from the STEP UP and STEP UP T2D phase 3 trials, which compared Wegovy® 7.2 mg, 2.4 mg, and placebo. The trials demonstrated a statistically significant difference in:
Mean change in body weight:
STEP UP: −18.7% with 7.2 mg vs. −15.6% with 2.4 mg vs. −3.9% with placebo; p<0.0001
- STEP UP T2D: −13.2% with 7.2 mg vs. −3.9% with placebo; p<0.0001
Body weight reduction of 5% or greater with Wegovy® 7.2 mg vs. placebo:
- STEP UP: odds ratio 12.1 [95% CI 8.3 to 17.6]; p<0.0001
- 12.1 times higher than placebo to achieve weight reduction of 5% or greater
- STEP T2D: odds ratio 10.0 [95% CI 6.0 to 16.9]; p<0.0001
- 10 times higher than placebo to achieve weight reduction of 5% or greater
However, higher doses were associated with increased rates of adverse effects, particularly gastrointestinal events and dysesthesia (abnormal sensations such as burning or stinging).
This new approval of a higher dose builds on the previous maximum of 2.4 mg and provides an additional tool for patients requiring further weight loss despite lifestyle interventions and standard therapy. However, treatment decisions should remain individualized, with consideration of tolerability, cost, and patient preference. As this is a newly approved dose, ongoing real-world data and long-term outcomes studies will be important to further define the role of high-dose semaglutide in clinical practice.
Published on June 30, 2026
References
- News Details. Novo Nordisk. Published 2026. Accessed April 29, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916516
- Wharton S, Freitas P, Jøran Hjelmesæth, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. Published online September 1, 2025. doi:https://doi.org/10.1016/s2213-8587(25)00226-8
- Lingvay I, Bergenheim SJ, Buse JB, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025;13(11):935-948. doi:https://doi.org/10.1016/S2213-8587(25)00225-6
- Office. Commissioner’s National Priority Voucher (CNPV) Pilot Program. U.S. Food and Drug Administration. Published 2025. https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program